id,name,study_number,protocol_id,study_name,protocol_title,therapeutic_area,indication,phase,blinded,randomized,status,study_start_date,study_end_date,enrollment_start_date,enrollment_end_date,fpfv_planned,fpfv_actual,lpfv_planned,lpfv_actual,sponsor,total_planned_subjects
a0B5f000000XmGrEAK,ONCO-2025-117,ONCO-2025-117,PROT-117,ONCO-2025-117,A Phase II Study of MK-8791 in Combination with Pembrolizumab for Metastatic Triple-Negative Breast Cancer,Oncology,Triple-Negative Breast Cancer,Phase 2,TRUE,TRUE,Active,9/15/2024,,10/1/2024,10/1/2025,10/10/2024,10/15/2024,8/15/2025,,PharmaTech Oncology,120
